The Long Run with Luke Timmerman
MurmurCast publishes AI-generated summaries of The Long Run with Luke Timmerman’s Podcast episodes — 2 summarized so far, covering Menin inhibitor development and mechanism of action, Troy Wilson's career trajectory and entrepreneurial journey, Farnesyl transferase inhibitors and combination therapy strategies, FDA approval pathway for Ziftimenib in AML, RAS inhibitor combinations and resistance mechanisms, San Diego biotech ecosystem and startup culture. Each summary distills the key insights, topics, and takeaways so you can decide what’s worth your time before pressing play.
Ep204: Troy Wilson on Precision Cancer Drugs and Combos
Troy Wilson, CEO of Cura Oncology, discusses his journey from mediocre student to serial biotech entrepreneur, the development of Ziftimenib (a Menin inhibitor approved for AML), and the company's strategy of combining precision cancer drugs like farnesyl transferase inhibitors with emerging RAS inhibitors to overcome treatment resistance.
Ep201: Jeremy Levin on Biotech in the Balance
Jeremy Levin, founder of Ovid Therapeutics and author of 'Biotech in the Balance,' discusses the systemic decline in public trust toward the biotechnology industry, tracing it from the Shkreli scandal through COVID-19 and into the current era of hostile policy. He argues the industry must recognize itself as strategically vital and offers ten commitments—including transparency, patient-centricity, and long-term capital formation—to rebuild its standing with the public and policymakers.